^
Association details:
Biomarker:No biomarker
Cancer:Acute Myelogenous Leukemia
Drug:magrolimab (ONO-7913) (CD47 inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: B - Late Trials
Title:

Forty Seven, Inc. Granted Fast Track Designation for Magrolimab (5F9) for the Treatment of Myelodysplastic Syndrome and Acute Myeloid Leukemia

Published date:
09/03/2019
Excerpt:
Forty Seven, Inc...announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to magrolimab (formerly known as 5F9) for the treatment of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML).